The Global Liquid Biopsy market has been estimated at USD 418.5 in 2016 and is projected to reach USD 2,112.3 million by 2024, at a CAGR of 22.5% during the forecast period from 2016 to 2024. Liquid biopsy is a cutting-edge non-invasive cancer diagnosis process which uses biofluids such as blood, urine, plasma, cerebrospinal fluid (CSF) for detecting various cancers. The liquid biopsy test is useful for identifying cancer in early stages. The liquid biopsy test uses various biomarkers such as circulating tumour cells (CTC), circulating nucleic acids and exosomes as a biomarker for diagnosis of cancer. In the patient body, above-mentioned biomarkers can be released in to body fluids by cancer cells. Among all samples, blood sample is extensively used for diagnosis of various cancers such as lung cancer, GIT cancer, breast cancer, and leukemia. Urine and cerebrospinal samples are mainly used for detection of prostate and brain cancers respectively. Market Dynamics: Major drivers in the global liquid biopsy market are increasing prevalence of various cancers such as lung cancer, breast cancer, GIT cancers and prostate cancers and rising accessibility of advanced diagnosis procedures. These factors are expected to drive growth of the global liquid biopsy market during the forecast period. Other prominent driving factors are increasing oncologists preference towards liquid biopsy procedure for detecting cancer and increasing number of biotechnology and pharmaceutical companies research and developments to discover anti-cancer drugs. In addition to this, increasing regulatory bodies’ approvals for various new non-invasive tests is also driving growth of global liquid biopsy market. However, high cost, reimbursement scenario and awareness are the major restraining factors are expecting to hamper global liquid biopsy market over the forecast period. By sample type, the global liquid biopsy market has been segment into blood, urine, and others (saliva, plasma, Cerebrospinal fluid (CSF)). By marker type, the global liquid biopsy market has been segment into circulating tumour Cells (CTCs), circulating tumour nucleic acids (ctNA), and exosomes. By disease indication, the global liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer (GIT), breast cancer, colorectal, prostate cancer, leukemia and others. In terms of value, Lung cancer disease indication segment is currently accounts for utmost revenue as compared to other disease indication segments in the global liquid biopsy market. While breast cancer and colorectal cancers disease indication segments are anticipated to contribute significant revenue in global liquid biopsy market by the end of 2024. By end user, the global liquid biopsy market has been segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. In terms of value, Cancer institute end user segment is expected to make significant incremental opportunity in global liquid biopsy market over the forecast period. The global liquid biopsy market has been segmented into five major regions: North America, Latin America, Europe, Europe, APAC, and Middle East & Africa (MEA). In 2016, North America is expected to account for the largest share and is expected to register a CAGR of 20.9% over the forecast period. This is owing to high adoption of novel advanced diagnostic technologies as well as increasing cancer prevalence in the U.S. and Canada. In terms of value, APAC region is estimated to be the fastest growing market and is expected to register a CAGR of 24.3% over the forecast period. By disease indication segment, Lung cancer disease segment in the APAC liquid biopsy market is expected to register a CAGR of 21.8% over the forecast period, owing to increasing lung cancer prevalence in this region. Major players in the global liquid biopsy market are BIOCEPT, INC., F. Hoffmann-La Roche Ltd., Qiagen N.V., Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., Silicon Biosystems, Sysmex Corporation, Trovagene, and Pathway Genomics Corporation.
Table of Content
1. Executive Summary 2. Assumptions and Acronyms 3. Research Methodology 4. Liquid Biopsy Market Overview 4.1. Liquid Biopsy Market Introduction 4.1.1. Market Definition 4.1.2. Market Taxonomy 4.2. Liquid Biopsy Market Dynamics (DROT) 4.2.1. Market Drivers 4.2.2. Market Restraints 4.2.3. Market Opportunities 4.2.4. Market Restraints 4.3. Pipeline Assessment, By Products 4.4. Product Penetration and Pricing Impact 5. Global Liquid Biopsy Market Forecast and Analysis, By Sample Type 5.1. Introduction 5.2. By Sample Type 5.2.1. Blood 5.2.2. Urine 5.2.3. Others (Plasma, Saliva, CSF) 6. Global Liquid Biopsy Market Forecast and Analysis, By Marker Type 6.1. Introduction 6.2. By Marker Type 6.2.1. CTCs (circulating tumor cells) 6.2.2. ctNA (circulating tumor nucleic acids) 6.2.3. Exosomes 7. Global Liquid Biopsy Market Forecast and Analysis, By End User 7.1. Introduction 7.2. By End User 7.2.1. Hospitals 7.2.2. Academic Institutes 7.2.3. Cancer Institutes 7.2.4. Diagnostic Centers 7.3. Market Attractiveness Analysis, By End User
